Consort Medical plc (CSRT.L) confirmed that the UK Medicines and Healthcare products Regulatory Agency or MHRA has granted Kind Consumer the variation to the first Marketing Authorisation awarded to the Voke nicotine inhaler, the subject of Bespak's development programme DEV200.
The first Marketing Authorisation for the Voke nicotine inhaler was received in September 2014. Voke will be commercialised by Nicovations, a wholly owned subsidiary of British American Tobacco Plc. (BATS.L, BTI).
As previously announced, the production facilities which will house the Voke® production line, are in place at Bespak in King's Lynn. Consort continues to work closely with Nicovations to complete scale up for full commercialisation, details of which will be announced by Nicovations at the appropriate time.
Voke is nicotine inhalation device for smokers. Voke involves no heat or combustion, and so produces no ash or smoke. It also requires no battery or other energy source, it is activated simply by the user inhaling.
Voke was developed by Kind Consumer Limited.
For comments and feedback: editorial@rttnews.com